- Home
- AIRS vs LUCD Comparison
AIRS vs LUCD Comparison
Compare AIRS & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- LUCD
- Stock Information
- Founded
- AIRS 2012
- LUCD 2018
- Country
- AIRS United States
- LUCD United States
- Employees
- AIRS N/A
- LUCD N/A
- Industry
- AIRS Medical/Nursing Services
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AIRS Health Care
- LUCD Health Care
- Exchange
- AIRS Nasdaq
- LUCD Nasdaq
- Market Cap
- AIRS 166.3M
- LUCD 140.7M
- IPO Year
- AIRS 2021
- LUCD 2021
- Fundamental
- Price
- AIRS $4.90
- LUCD $1.16
- Analyst Decision
- AIRS Hold
- LUCD Strong Buy
- Analyst Count
- AIRS 3
- LUCD 4
- Target Price
- AIRS $3.75
- LUCD $3.94
- AVG Volume (30 Days)
- AIRS 698.1K
- LUCD 1.1M
- Earning Date
- AIRS 08-08-2025
- LUCD 08-11-2025
- Dividend Yield
- AIRS N/A
- LUCD N/A
- EPS Growth
- AIRS N/A
- LUCD N/A
- EPS
- AIRS N/A
- LUCD N/A
- Revenue
- AIRS $172,101,000.00
- LUCD $4,173,000.00
- Revenue This Year
- AIRS N/A
- LUCD $91.46
- Revenue Next Year
- AIRS $4.90
- LUCD $213.42
- P/E Ratio
- AIRS N/A
- LUCD N/A
- Revenue Growth
- AIRS N/A
- LUCD 39.89
- 52 Week Low
- AIRS $1.53
- LUCD $0.72
- 52 Week High
- AIRS $9.20
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- AIRS 58.37
- LUCD 38.38
- Support Level
- AIRS $4.62
- LUCD $1.13
- Resistance Level
- AIRS $5.28
- LUCD $1.34
- Average True Range (ATR)
- AIRS 0.48
- LUCD 0.07
- MACD
- AIRS -0.07
- LUCD -0.01
- Stochastic Oscillator
- AIRS 57.25
- LUCD 14.29
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.